Clinical data
Trade names Xiidra
AHFS/ xiidra
Routes of
Eye drops
ATC code none
Legal status
Legal status
Synonyms SAR-1118
CAS Number 1025967-78-5
PubChem (CID) 11965427
ChemSpider 10139520
UNII 038E5L962W
KEGG D10374
ChEBI CHEBI:133023 YesY
Chemical and physical data
Formula C29H24Cl2N2O7S
Molar mass 615.48 g·mol−1
3D model (Jmol) Interactive image

Lifitegrast (trade name Xiidra) is a drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is applied in the form of eye drops.[1]

Adverse effects

Common side effects in clinical trials were eye irritation, discomfort, blurred vision, and dysgeusia (a distortion of the sense of taste).[2]


Mechanism of action

Lifitegrast inhibits an integrin, lymphocyte function-associated antigen 1 (LFA-1), from binding to intercellular adhesion molecule 1 (ICAM-1). This mechanism down-regulates inflammation mediated by T lymphocytes.[1][3]


Lifitegrast was initially designed and developed by SARcode Bioscience[4] which was acquired by Shire in 2013,[5] who submitted a new drug application to the US Food and Drug Administration (FDA) in March 2015. The FDA granted Shire a priority review a month later, and requested additional clinical data, which were supplied in January 2016. The drug was finally approved on 11 July 2016.[6][7]

See also


  1. 1 2 Tauber, J (December 2015). "Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study". Ophthalmology. 122 (12): 2423–31. doi:10.1016/j.ophtha.2015.08.001. PMID 26365210.
  2. Patient in formation for xiidra.
  3. Murphy, C. J.; Bentley, E; Miller, P. E.; McIntyre, K; Leatherberry, G; Dubielzig, R; Giuliano, E; Moore, C. P.; Phillips, T. E.; Smith, P. B.; Prescott, E; Miller, J. M.; Thomas, P; Scagliotti, R; Esson, D; Gadek, T; O'Neill, C. A. (2011). "The Pharmacologic Assessment of A Novel Lymphocyte Function-Associated Antigen-1 Antagonist (SAR 1118) for the Treatment of Keratoconjunctivitis Sicca in Dogs". Investigative ophthalmology & visual science. 52 (6): 3174–80. doi:10.1167/iovs.09-5078. PMID 21330663.
  4. Semba, Charles; Gadek, Thomas (2016). "Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease". Clinical Ophthalmology: 1083. doi:10.2147/OPTH.S110557.
  5. "Shire To Acquire Sarcode Bioscience, Expands Presence In Ophthalmology". 25 March 2013.
  6. "FDA Approves Shire's Xiidra". 11 July 2016.
  7. Xiidra (lifitegrast) FDA Approval History
This article is issued from Wikipedia - version of the 9/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.